SafeBeat goes beyond diagnostics to guide cardiac care. Our artificial intelligence technology powers the SafeBeat platform to expand access to remote patient monitoring (RPM)using third party FDA-cleared cardiac monitoring devices (mobile ECG, mobile cardiac telemetry, and implantable cardiac monitor) and software-enable therapeutic monitoring, all from your phone.
Our unique algorithms and software platform are designed to help clinicians quickly assess important information about their patients, without being buried in alerts and notifications. All software is streamlined for use from a mobile phone, with explainable AI and custom tools that don’t just display diagnostic information, but recommend treatment steps customized for the patient.
With patient and clinician experience as first priority, our platforms unlock the full capabilities of digital health and remote care
Our proprietary machine learning algorithms power our solutions, and we are making our software available to power your products as well. From ECG interpretation to treatment management, our world-class AI delivers efficiency and streamlined insights.
Caution: Product under development.. Not currently for sale. Limited by Federal (or United States) Law to Investigational Use Only.
Heart Rhythm Society plays a key role in supporting new technologies like yours, which respond to the needs of both patients and healthcare systems and help advance our specialty.
Your product has the real potential to upend the current in-patient workflow of patients…and to dramatically improve the care of patients who currently require in-patient monitoring for drug initiation, and may thus improve patient care, workflow and cost effectiveness.
I expect the technology developed…to make an immediate and widespread impact on the treatment of atrial fibrillation patients in the VA system and in the broader community, by improving access and reducing health disparities.
In assessing the digital health landscape today, the capability of your technology to go beyond diagnostics to bring mortality reducing medications to larger populations will both reduce healthcare costs and improve cardiovascular outcomes.
The alternative you offer to current standard of care is not just incrementally better but radically improved, and your [team’s] backgrounds make you uniquely qualified to solve the pain points facing doctors and patients.
Over the summer, I was looking to get an insight on how it would be to work in a startup company. What I got in return was far greater than what I have imagined. Working for a Y Combinator company gave me the opportunity to work with highly competent individuals that I learned a tremendous amount from. As a machine learning intern, I was given the chance to actually contribute to their product, which lead to me working on something that actually had meaning. If you’re looking to work for a company where your contributions actually matter, then Safebeat Rx is one that I would highly recommend.
Dr. Navara is a bioengineer and cardiologist specializing in heart rhythm disorders. She has been internationally recognized for her atrial fibrillation research, and she has led numerous award-winning medical innovation teams within academia (Stanford, UCSF, Wash U, MIT, Olin College of Engineering, UT Southwestern) and industry (Boston Scientific, Preserve, Harvard Brigham and Women’s Hospital). She is an appointed member of the National ACC Heart Rhythm Leadership Council and is HRS delegate to the AMA, directly shaping arrhythmia treatment guidelines.
Dr. Patel is a physical medicine and interventional pain physician from Harvard, Emory, Wash U, and NJIT with masters-level expertise in applied mathematics/numerical methods and translational research. He was a White House Presidential Leadership Scholar finalist and executive board member of multiple professional medical societies. Prior to SafeBeat Rx, he built a private practice clinic centered on a fully integrated remote monitoring platform he developed to facilitate care during the COVID-19 pandemic.
Dr. Navara is a bioengineer and cardiologist specializing in heart rhythm disorders. She has been internationally recognized for her atrial fibrillation research, and she has led numerous award-winning medical innovation teams within academia (Stanford, UCSF, Wash U, MIT, Olin College of Engineering, UT Southwestern) and industry (Boston Scientific, Preserve, Harvard Brigham and Women’s Hospital). She is an appointed member of the National ACC Heart Rhythm Leadership Council and is HRS delegate to the AMA, directly shaping arrhythmia treatment guidelines.
Dr. Patel is a physical medicine and interventional pain physician from Harvard, Emory, Wash U, and NJIT with masters-level expertise in applied mathematics/numerical methods and translational research. He was a White House Presidential Leadership Scholar finalist and executive board member of multiple professional medical societies. Prior to SafeBeat Rx, he built a private practice clinic centered on a fully integrated remote monitoring platform he developed to facilitate care during the COVID-19 pandemic.
Mr. Higgins brings 13 years’ experience in software engineering and artificial intelligence platforms, including managing the entire end-to-end software development lifecycle. As Founding Engineering Director for a Non-Profit R&D lab in Silicon Valley and Product Innovation Manager at Athenahealth, he brought countless products to end-users including executing a 150,000+ user, cloud SaaS environment interfacing with 29,000 healthcare providers.
Mr. Alvarez is a Senior Full-stack and Machine learning Software Engineer who has over ten years of experience, including at Fortune 500 companies, like Morgan Stanley, where he worked as a Senior Software engineer. He has a background in signal processing and telecommunication, and previously helped scale Wise.com through to a successful IPO as part of their debit card and machine learning engineering teams.
Mr. Sackett, is SafeBeat’s Head of Operations and Technical Operations Lead, and he is a former senior engineer at Genentech, where he worked for 8 years and previously managed top software development teams. He also brings a wealth of knowledge from the pharmaceutical industry regarding clinical trials and commercialization, having helped with the rollout of novel products to millions of people around the globe. He leads SafeBeat’s early partnerships and growth strategies.
Rania deLeon is a biomedical engineer who brings seven years of experience in the medical device industry in both quality assurance and regulatory affairs, specifically in the area of cardiac electrophysiology. In her career, she has gotten medical device approvals from the FDA, Health Canada, European Union, and Australia, and has built electronic quality management systems from the ground up. Her approved devices are being used by thousands of cardiologists across the world today.